ORGO

Organogenesis Holdings Inc. [ORGO] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ORGO Stock Summary

Top 10 Correlated ETFs

ORGO


Top 10 Correlated Stocks

ORGO


In the News

06:29 29 Mar 2024 ORGO

Why Organogenesis Holding Stock Plummeted by 18% Today

To put it charitably, the market wasn't impressed with the company's recent performance. They traded out of the stock following the publication of quarterly and annual results.

11:06 29 Mar 2024 ORGO

Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript

Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript

06:46 29 Mar 2024 ORGO

Organogenesis (ORGO) Reports Break-Even Earnings for Q4

Organogenesis (ORGO) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.06 per share a year ago.

04:05 29 Mar 2024 ORGO

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024

CANTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that fourth quarter and fiscal year 2023 financial results will be reported after the market closes on Thursday, February 29th.

01:32 29 Mar 2024 ORGO

Are You Looking for a Top Momentum Pick? Why Organogenesis (ORGO) is a Great Choice

Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.

11:17 29 Mar 2024 ORGO

Best Momentum Stocks to Buy for January 5th

ORGO, CALM and NET made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 5, 2024.

08:16 29 Mar 2024 ORGO

New Strong Buy Stocks for January 5th

ORGO, CALM, W, NET and EVH have been added to the Zacks Rank #1 (Strong Buy) List on January 5, 2024.

01:32 29 Mar 2024 ORGO

Organogenesis (ORGO) is a Great Momentum Stock: Should You Buy?

Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.

09:46 29 Mar 2024 ORGO

5 Reasons Why Small-Cap Stocks Can Surge in 2024: 5 Top Picks

Small-cap stocks should rally ahead due to cheaper valuation, cooling inflation data and hopes of Fed rate cuts in 2024. Against this backdrop, Organogenesis (ORGO), Riskified (RSKD), Hooker Furniture Corporation (HOFT), Stoneridge (SRI) and VirTra (VTSI) emerge as winning picks.

10:32 29 Mar 2024 ORGO

Here Is Why Bargain Hunters Would Love Fast-paced Mover Organogenesis (ORGO)

Organogenesis (ORGO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

ORGO Financial details

Company Rating
Neutral
Market Cap
344.42M
Income
13.89M
Revenue
433.14M
Book val./share
2.13
Cash/share
0.8
Dividend
-
Dividend %
-
Employees
862
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
25.92
Forward P/E
28.4
PEG
-21.16
P/S
1.27
P/B
2.05
P/C
3.55
P/FCF
-159.17
Quick Ratio
2.3
Current Ratio
2.77
Debt / Equity
0.29
LT Debt / Equity
0.22
-
-
EPS (TTM)
0.11
EPS next Y
0.1
EPS next Q
-0.02
EPS this Y
-68.58%
EPS next Y
-9.78%
EPS next 5Y
-5.03%
EPS last 5Y
NAN%
Revenue last 5Y
10.66%
Revenue Q/Q
-8.18%
EPS Q/Q
-104.66%
-
-
-
-
SMA20
-20.76%
SMA50
-33.25%
SMA100
19.91%
Inst Own
34%
Inst Trans
0.87%
ROA
5%
ROE
8%
ROC
0.05%
Gross Margin
76%
Oper. Margin
4%
Profit Margin
5%
Payout
-
Shs Outstand
131.96M
Shs Float
77.46M
-
-
-
-
Target Price
-
52W Range
1.795-4.705
52W High
-29%
52W Low
+184%
RSI
44.56
Rel Volume
0.35
Avg Volume
713.01K
Volume
253.05K
Perf Week
3.27%
Perf Month
-22.83%
Perf Quarter
-0.18%
Perf Half Y
9.65%
-
-
-
-
Beta
1.576
-
-
Volatility
0.09%, 0.34%
Prev Close
2.9%
Price
2.84
Change
6.77%

ORGO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
2.813.143.653.473.3
Net income per share
-0.440.160.730.120.04
Operating cash flow per share
-0.360.060.480.190.24
Free cash flow per share
-0.43-0.130.24-0.070.05
Cash per share
0.650.780.890.790.8
Book value per share
0.61.361.892.042.12
Tangible book value per share
0.10.81.461.661.78
Share holders equity per share
0.61.361.892.042.12
Interest debt per share
1.180.891.090.970.63
Market cap
446.56M811.27M1.19B349.89M536.74M
Enterprise value
486.99M811.64M1.2B371.2M551.75M
P/E ratio
-11.0447.0712.5922.53108.54
Price to sales ratio
1.712.42.530.781.24
POCF ratio
-13.32119.2919.1314.0717.36
PFCF ratio
-11.23-56.5638.55-38.7181.91
P/B Ratio
8.035.554.91.321.93
PTB ratio
8.035.554.91.321.93
EV to sales
1.872.42.570.821.27
Enterprise value over EBITDA
-24.3323.213.449.2113.87
EV to operating cash flow
-14.53119.3419.4314.9317.85
EV to free cash flow
-12.25-56.5839.15-41.0784.2
Earnings yield
-0.090.020.080.040.01
Free cash flow yield
-0.09-0.020.03-0.030.01
Debt to equity
1.810.580.550.470.29
Debt to assets
0.460.290.30.280.17
Net debt to EBITDA
-2.020.010.210.530.38
Current ratio
2.12.562.772.972.8
Interest coverage
-3.272.4310.0811.17.45
Income quality
0.830.380.651.66.25
Dividend Yield
0.130000
Payout ratio
-1.4300.020.040
Sales general and administrative to revenue
0.760.590.520.620
Research and developement to revenue
0.060.060.070.090.1
Intangibles to total assets
0.210.20.120.110.1
Capex to operating cash flow
0.19-3.11-0.5-1.36-0.79
Capex to revenue
-0.02-0.06-0.07-0.08-0.06
Capex to depreciation
-0.66-2.83-1.87-1.88-1.04
Stock based compensation to revenue
000.010.010.02
Graham number
2.422.215.582.341.34
ROIC
-0.170.110.250.040.02
Return on tangible assets
-0.230.070.240.040.01
Graham Net
-0.69-0.07-0.1-0.01-0.01
Working capital
65.71M106.13M144.97M147.59M144.54M
Tangible asset value
9.25M86.69M187.59M216.11M234.02M
Net current asset value
-39.5M25.93M25.76M38.92M43.68M
Invested capital
1.810.580.550.470.29
Average receivables
36.72M48.08M69.63M85.96M85.72M
Average payables
23.78M25.88M26.36M30.83M31.53M
Average inventory
18.12M25.36M26.41M24.9M26.52M
Days sales outstanding
55.0561.2964.372.4169.1
Days payables outstanding
136.4397.7393.77112.3690.91
Days of inventory on hand
110.14116.279.9786.1383.6
Receivables turnover
6.635.965.685.045.28
Payables turnover
2.683.733.893.254.01
Inventory turnover
3.313.144.564.244.37
ROE
-0.730.120.390.060.02
Capex per share
-0.07-0.2-0.24-0.26-0.19

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.880.820.890.830.76
Net income per share
0.06-0.020.040.090
Operating cash flow per share
0.06-0.040.070.130.08
Free cash flow per share
-0.02-0.10.010.080.06
Cash per share
0.780.680.690.750.8
Book value per share
2.032.012.072.112.13
Tangible book value per share
1.651.641.711.761.79
Share holders equity per share
2.032.012.072.112.13
Interest debt per share
0.950.940.950.950.62
Market cap
352.17M279.21M435.89M417.57M535.45M
Enterprise value
373.48M312.87M471.73M444.37M550.46M
P/E ratio
11.76-23.5120.58.62-235.67
Price to sales ratio
3.052.593.723.855.37
POCF ratio
45.15-54.9950.4224.9550.45
PFCF ratio
-123.31-22.09380.0338.8273.46
P/B Ratio
1.331.061.611.511.92
PTB ratio
1.331.061.611.511.92
EV to sales
3.232.914.024.095.52
Enterprise value over EBITDA
42.84165.9835.6655.278.87
EV to operating cash flow
47.88-61.6254.5626.5551.87
EV to free cash flow
-130.77-24.75411.2741.3175.52
Earnings yield
0.02-0.010.010.030
Free cash flow yield
-0.01-0.0500.030.01
Debt to equity
0.470.460.460.450.29
Debt to assets
0.280.270.280.270.17
Net debt to EBITDA
2.4417.862.713.332.15
Current ratio
2.972.852.952.772.8
Interest coverage
-138.77-6.1316.41-18.131.29
Income quality
1.041.711.635.29-18.68
Dividend Yield
00000
Payout ratio
000.0100
Sales general and administrative to revenue
0.5500.600
Research and developement to revenue
0.10.10.090.10.12
Intangibles to total assets
0.110.110.10.10.1
Capex to operating cash flow
-1.371.49-0.87-0.36-0.31
Capex to revenue
-0.09-0.07-0.06-0.06-0.03
Capex to depreciation
-2.34-1.29-2.17-1.58-0.53
Stock based compensation to revenue
0.020.020.020.020.02
Graham number
1.621.011.372.090.46
ROIC
0.01-0.010.010.030
Return on tangible assets
0.02-0.010.010.030
Graham Net
-0.01-0.09-0.05-0.05-0.01
Working capital
147.59M140.75M142.98M144.09M144.54M
Tangible asset value
216.11M215.37M224.18M230.99M234.02M
Net current asset value
38.92M34.42M37.4M39.79M43.68M
Invested capital
0.470.460.460.450.29
Average receivables
91.28M90.74M92.82M91.45M85.64M
Average payables
35.14M31.32M28.85M27.09M28.75M
Average inventory
24.73M25.16M25.45M26.63M28.08M
Days sales outstanding
69.6976.9471.8274.0374.06
Days payables outstanding
107.33102.5393.6793.4786.76
Days of inventory on hand
82.2786.3986.7497.3879.79
Receivables turnover
1.291.171.251.221.22
Payables turnover
0.840.880.960.961.04
Inventory turnover
1.091.041.040.921.13
ROE
0.03-0.010.020.040
Capex per share
-0.08-0.06-0.06-0.05-0.03

ORGO Frequently Asked Questions

What is Organogenesis Holdings Inc. stock symbol ?

Organogenesis Holdings Inc. is a US stock , located in Canton of Ma and trading under the symbol ORGO

What is Organogenesis Holdings Inc. stock quote today ?

Organogenesis Holdings Inc. stock price is $2.84 today.

Is Organogenesis Holdings Inc. stock public?

Yes, Organogenesis Holdings Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap